# Efficacy-Safety-Immunogenicity Study of CBT124&EU-sourced Avastin® in Stage 4 NSCLC

> **NCT02879097** · PHASE3 · UNKNOWN · sponsor: **Cipla BioTec Pvt. Ltd.** · enrollment: 200 (estimated)

## Conditions studied

- Non-Small Cell Lung Carcinoma

## Interventions

- **BIOLOGICAL:** CBT124
- **BIOLOGICAL:** EU-sourced Avastin®
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT02879097
- **Lead sponsor:** Cipla BioTec Pvt. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-12
- **Primary completion:** 2017-12
- **Final completion:** 2018-05
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2016-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02879097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02879097, "Efficacy-Safety-Immunogenicity Study of CBT124&EU-sourced Avastin® in Stage 4 NSCLC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02879097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*